Logo Image
News|Articles|May 6, 2026

Eli Lilly Opens First Dedicated Genetic Medicine Facility

Listen
0:00 / 0:00

The facility opening corresponds with a new $4.5 billion capital commitment across two of Lilly's three sites in Lebanon, Indiana.

Eli Lilly today opened Lilly Lebanon Advanced Therapies, its first dedicated genetic medicine manufacturing facility, located in Lebanon, Indiana.¹ The move signals a broader industry inflection point as the cell and gene therapy (CGT) market accelerates toward a near-tripling of approved products by the end of the decade.

Alongside the facility opening, Lilly announced an additional $4.5 billion investment across two of its three Lebanon sites, bringing the company's total Indiana capital expansion commitments since 2020 to more than $21 billion and its total US commitments since 2020 to more than $50 billion.2

The Lebanon Advanced Therapies facility is designed to support both clinical and commercial production of advanced therapies that target disease at the genetic level. According to the company, it will encompass a full spectrum of genetic medicine modalities, ranging from research-stage development through large-scale commercial supply.2 In a press release, Lilly stated that designing and building for these modalities required "developing new manufacturing processes without established commercial precedent."2

The new facility is also the first of three planned sites at the company’s Lebanon campus, which will also include an active pharmaceutical ingredient (API) facility and the Lilly Medicine Foundry.2

Why Does the Lilly Lebanon Advanced Therapies Opening Matter?

The significance of Lilly's facility opening extends beyond the company's capital spending plan. It arrives at a moment when the broader CGT industry faces significant growth projections.

According to Cardinal Health's 2026 Advanced Therapy Industry Report, which released last month, there are currently 61 advanced therapies approved in the United States, and that number is projected to nearly triple by 2030.1 The report also notes that while oncology remains the dominant therapeutic area for CGTs, innovation is accelerating across additional disease states including neurology, rheumatology, ophthalmology, and cardiology.1

For Lilly, building a dedicated genetic medicine facility of this scope reflects the growing advanced therapy pipeline.

What Is the Scale of Lilly's Financial Commitment?

The Lebanon Advanced Therapies facility is the first of three planned sites on Lilly's Lebanon campus, which will eventually also include Lilly Lebanon API and the Lilly Medicine Foundry.2 The Lebanon API site is slated to open in 2027 and, according to Lilly, will be the largest API production site in U.S. history.2

"From genetic medicines that could one day prevent disease at its source, to Foundayo, a pill making weight loss treatment accessible to millions, we are not just discovering the medicines of the future — we are building the world's most advanced plants to make them,” Lilly chair and CEO, David A. Ricks, said in the release.

The Lebanon campus investment also reflects Lilly's broader pipeline priorities. In addition to existing commitments to manufacture Zepbound (tirzepatide) and Mounjaro (tirzepatide) at the Lebanon API site, the company announced that the campus will include planned production of Foundayo (orforglipron), Lilly's first FDA-approved once-daily oral pill for weight loss, and retatrutide, an investigational triple hormone receptor agonist in late-stage development for obesity and cardiometabolic disease.2

What Does Lebanon Advanced Therapies Signal for Specialty Pharma?

CGT approvals are expected to triple by 2030 and expand from a concentrated set of approved therapies to a broader, more diverse field.2

Whether other major pharmaceutical companies follow Lilly's lead in building dedicated genetic medicine production facilities, rather than relying on contract development and manufacturing organizations or shared production lines, will be a key question for CGT commercialization over the next several years.

References

Related Content